首页> 外文期刊>Bone marrow transplantation >Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT
【24h】

Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT

机译:在降低强度的调节方案和同种SCT后,淋巴瘤患者的疾病状况是比组织学更可靠的预测因素

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We analyzed 113 patients with lymphoma who underwent allogeneic transplantation with reduced-intensity conditioning (allo-RIC) regimens at a single institution, from February 2001 through November 2009, searching for factors predictive of the outcome. At the time of transplantation, 60% of patients were in CR, 29% in PR and 11% had progressive or stable disease. At a median follow-up of 34 months (confidence interval (CI) 17-45), the 3-year OS and PFS were 59% (CI 48-68%) and 51% (CI 41-61%), respectively. The 100-day and 2-year nonrelapse mortalities (NRM) were 6% and 28% (CI 20-35%), respectively. Grade II-IV acute GVHD (aGVHD) incidence was 38%, and the global incidence of chronic GVHD was 33%. In univariate analysis, OS was influenced by disease status before allo-RIC; aGVHD negatively affected on survival. Similarly, PFS was influenced only by disease status. Histological subtype did not affect OS or PFS. We conclude that disease status at the time of transplantation significantly influences survival in patients receiving allo-RIC for lymphoma, whereas histological subtype does not. This reinforces the need to administer more effective debulking treatments to lymphoma patients, for optimal benefit of allogeneic immune recognition of minimal residual disease, independently from lymphoma histology.
机译:我们分析了2001年2月至2009年11月在单一机构接受低强度调节(allo-RIC)方案的同种异体移植的113例淋巴瘤患者,以寻找可预测结果的因素。移植时,60%的患者患有CR,29%的患者患有PR,11%的患者患有进行性或稳定的疾病。在34个月的中位随访(置信区间(CI)17-45)中,三年OS和PFS分别为59%(CI 48-68%)和51%(CI 41-61%)。 100天和2年非复发死亡率(NRM)分别为6%和28%(CI 20-35%)。 II-IV级急性GVHD(aGVHD)发生率为38%,全球慢性GVHD发生率为33%。在单因素分析中,在同种RIC之前,OS受疾病状况的影响。 aGVHD对生存产生负面影响。同样,PFS仅受疾病状况的影响。组织学亚型不影响OS或PFS。我们得出的结论是,移植时的疾病状态显着影响接受同种异位RIC治疗淋巴瘤的患者的生存,而组织学亚型则不。这就增强了对淋巴瘤患者进行更有效的减量治疗的需求,以获得与淋巴瘤组织学无关的最小限度残留疾病的同种异体免疫识别的最佳益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号